Global LHON Patient Advocacy Landscape — 2026

Executive summary

No single global LHON advocacy organization exists. Patient support, research funding, and awareness are distributed across mitochondrial disease foundations (broader scope) and LHON-specific groups (narrower scope) operating independently in each country. The International Mito Patients (IMP) coalition represents the closest thing to a unified international structure, coordinating 16 national organizations since 2011.

Key findings

1. Core organizations by country

2. Funding capacity varies enormously

• UMDF: $17M+ lifetime research funding, $50k-$100k active grant cycles
• Mito Foundation Australia: Research and Medical Grant Program (amounts not publicly disclosed)
• Vision Hope Now: LHON-specific funding but smaller scale
• Most national orgs focus on patient support, not research grants

3. Coverage gaps

• No strong LHON-specific org for continental Europe (Italian Mitocon handles mito broadly; France/Germany rely on mito disease umbrella orgs)
• No India, South America, or African LHON advocacy presence identified
• LHON PLUS (LHON with neurological symptoms) is served only by LHON PLUS Global — an underserved sub-population

4. Patient registries

• mitoSHARE (UMDF): 2,200+ participants, next-generation registry with biorepository
• MSeqDR: Long-standing genomic/clinical data consortium (UMDF-funded since 2014)
• Cure Mito Foundation: Largest Leigh syndrome registry (400+ participants, 40+ countries)
• No dedicated global LHON registry identified — fragmented by country and org

Implications

For researchers: UMDF’s mitoSHARE is the best existing infrastructure for LHON patient recruitment and natural history studies. Collaboration with UMDF’s scientific advisory board (which includes Rustum Karanjia) could open patient cohort access.

For advocacy orgs: Coordination gaps — particularly the lack of LHON-specific advocacy in continental Europe — represent concrete opportunities for IMP to catalyze new national groups or for existing orgs to expand.

For patients and families: Geographic location largely determines access to advocacy support. US/UK/Canada/Australia patients have multiple options; patients elsewhere often have only broader mito disease orgs available.

For sponsors: Supporting international coordination (e.g., funding IMP’s LHON working group) would have multiplicative effect — one dollar reaching 16 national communities.

Method and verification

Data compiled from the organizations’ own public websites and the International Mito Patients coalition member list. Funding figures cited from UMDF public grant program documentation. Estimated patient prevalence (1 in 68,403 in Australia) from Mito Foundation Australia’s public LHON page.